Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	50.21B +5.4%
Revenue (ttm)	6.13B +40.8%
Net Income	2.68B +46.8%
EPS	5.94 +46.3%
Shares Out	450.00M
PE Ratio	18.79
Forward PE	17.43
Dividend	1.20 (1.08%)
Ex-Dividend Date	Sep 2, 2026

Volume	9,574,765
Open	105.50
Previous Close	106.25
Day's Range	105.20 - 112.36
52-Week Range	78.82 - 138.30
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company’s lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2,272
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2025, SHA:688578's revenue was 5.19 billion, an increase of 45.80% compared to the previous year's 3.56 billion. Earnings were 2.19 billion, an increase of 53.10%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error